 Theravance Biopharma Inc NASDAQ: TBPH has announced top-line results from its Phase 2 study evaluating nezulcitinib for hospitalized patients with confirmed COVID-19 associated acute lung injury and impaired oxygenation. Nezulcitinib is an investigational, inhaled, lung-selective, pan-Janus kinase JAK inhibitor. 